30006000330066003300660036007200
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)

30006000330066003300660036007200
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)
The TGFBR3/MGEA5 fusion gene (t(1;10)(p22;q24)) is seen in Hemosiderotic Fibrolipomatous Tumour (Hemosiderotic Fibrolipomatous Liposarcoma with Fibroblastic Deposition, HFLT), Pleomorphic Hyalinizing Angiectatic Tumor ( Pleomorphic Hyalinizing Angiectatic Tumor, PHAT), and Myxoinflammatory Fibroblastic Sarcoma (Mucinous Inflammatory Fibroblastic Sarcoma, MIFS).There is a correlation between HFLT and MIFS, PHAT, which represent morphologic variants at different growth stages in the same genetically altered tumor type, and of these, only MIFS has metastatic potential. MIFS has metastatic potential;
A BRAF gene translocation was found in some MIFS lacking the TGFBR3-MGEA5 translocation.